FDA Expands Access to Spravato
FDA Expands Access to Spravato Treatment, Now Available Without the Need for an Oral Antidepressant for Eligible Patients
Imagine Healthcare is excited to announce that Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. This groundbreaking decision marks a significant advancement in mental health care, offering new hope for individuals who have struggled with traditional antidepressants that either cause intolerable side effects or fail to provide effective relief.
Spravato, previously only available as part of a broader treatment regimen alongside oral antidepressants, has now received FDA approval to be used independently, creating a new pathway for those suffering from treatment-resistant depression (TRD). This new guideline expands access to the innovative nasal spray treatment, which is already known for its rapid-acting and transformative effects in patients with major depressive disorder. It is also covered by most major insurance plans including Medicaid and Medicare.
“This approval is a game changer for patients who have experienced little success with conventional antidepressants,” said Dr. Rachel Norris, founder of Imagine Healthcare. “Many of our clients have tried numerous antidepressants, often facing frustrating side effects or limited results. Now, with Spravato as a stand-alone treatment, we can provide an alternative that may bring significant, positive change for these individuals.”
Click here to learn more about Spravato!